studies

melanoma (ML), pembrolizumab (10mg/kg) vs. chemotherapy, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.74 [0.57; 0.96] 0.74[0.57; 0.96]KEYNOTE-002 (10 mg/kg), 201510%360NAnot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.50 [0.39; 0.64] 0.50[0.39; 0.64]KEYNOTE-002 (10 mg/kg), 201510%360NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 8.16 [3.74; 17.80] 8.16[3.74; 17.80]KEYNOTE-002 (10 mg/kg), 201510%360NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.76 [0.45; 1.26] 0.76[0.45; 1.26]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.54 [0.32; 0.91] 0.54[0.32; 0.91]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] 1.92[0.06; 57.48]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.65 [0.70; 3.87] 1.65[0.70; 3.87]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 2.73 [0.85; 8.76] 2.73[0.85; 8.76]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] 0.96[0.02; 48.41]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.05 [0.00; 0.88] 0.05[0.00; 0.88]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39] 0.96[0.06; 15.39]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39] 0.96[0.06; 15.39]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 2.90 [0.30; 28.13] 2.90[0.30; 28.13]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] 0.96[0.02; 48.41]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] 0.96[0.02; 48.41]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.28 [0.28; 5.81] 1.28[0.28; 5.81]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Dry skin TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] 0.96[0.02; 48.41]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.05; 1.10] 0.23[0.05; 1.10]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 3.85 [0.17; 86.06] 3.85[0.17; 86.06]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] 0.96[0.02; 48.41]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] 0.96[0.02; 48.41]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] 0.96[0.02; 48.41]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.07 [0.00; 1.17] 0.07[0.00; 1.17]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] 1.92[0.06; 57.48]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.48 [0.02; 14.29] 0.48[0.02; 14.29]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12] 0.23[0.03; 2.12]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.08 [0.00; 1.39] 0.08[0.00; 1.39]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] 1.92[0.06; 57.48]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] 0.96[0.02; 48.41]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.24 [0.01; 5.29] 0.24[0.01; 5.29]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 5.81 [0.29; 116.90] 5.81[0.29; 116.90]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] 0.96[0.02; 48.41]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] 0.96[0.02; 48.41]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12] 0.23[0.03; 2.12]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Uveitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] 1.92[0.06; 57.48]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Vitiligo TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] 0.96[0.02; 48.41]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12] 0.23[0.03; 2.12]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-23 06:01 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 2,283,284,70,235,285,68,127,128,286,69,129 - treatments: 575

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons